FDCDDQ
TVTX icon

Federation des caisses Desjardins du Quebec’s Travere Therapeutics TVTX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.91K Hold
300
– – ﹤0.01% 2363
2025
Q4 		$11.5K Buy
+300
New +$9.76K ﹤0.01% 2210

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's TVTX Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec held its Travere Therapeutics (TVTX) position steady in Q1 2026 at 300 shares worth $8.91K. The position accounts for ﹤0.01% of the portfolio, ranked #2363.

Federation des caisses Desjardins du Quebec first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $11.5K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Federation des caisses Desjardins du Quebec held 300 shares of Travere Therapeutics worth $8.91K as of Q1 2026.
  • Federation des caisses Desjardins du Quebec left its Travere Therapeutics share count unchanged in Q1 2026.
  • Travere Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #2363 holding.
  • Federation des caisses Desjardins du Quebec first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Federation des caisses Desjardins du Quebec's Travere Therapeutics position peaked at $11.5K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.